Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Down 5.11%
As of Thursday, October 08, MoonLake Immunotherapeutics’s MLTX share price has dipped by 5.11%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Commentary & Analysis
Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Down 6.58%
As of Wednesday, September 23, MoonLake Immunotherapeutics’s MLTX share price has dipped by 6.58%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Down 6.43%
As of Wednesday, September 09, MoonLake Immunotherapeutics’s MLTX share price has dipped by 6.43%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Up 5.48%
As of Friday, August 21, MoonLake Immunotherapeutics’s MLTX share price has surged by 5.48%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Down 6.92%
As of Tuesday, August 11, MoonLake Immunotherapeutics’s MLTX share price has dipped by 6.92%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | MLTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $900.4 | $239.3 | 45% |
|
| Shares Out (Mil) | 73.9 | 54.0 | 56% |
|
| Institutional Ownership | 88.6% | 93.1% | 56% |
|
| Float (Mil) | 55.5 | 41.4 | 49% |
|
| Beta | 1.08 | 0.95 | 65% |
|
| Avg Daily Volume (000s) | 2,039 | 613 | 81% |
|
| Price Change (52-week) |
14.0% | 49.1% | 65% |
|
| Growth | MLTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 9 | |
| Current EPS | ($0.781) | ($3.379) | ($3.326) | |
| Month Ago EPS | ($0.781) | ($3.379) | ($3.326) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.924) | ($3.838) | ($3.430) | |
| Year/Year Chg | (6.6%) | (4.2%) | (13.8%) | |
| Financials | MLTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($264) | ($44) | 5% |
|
| EPS (TTM) | ($3.814) | ($1.600) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($225) | ($34) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $171 | $2 | 83% |
|
| Long-Term Debt (Q1) (Mil) | $100 | $4 | 45% |
|
| Enterprise Value (Q1) (Mil) | $533 | $175 | 34% |
|
| Valuation | MLTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.07 | 2.30 | 54% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MLTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (51.0%) | (47.6%) | 11% |
|
| ROE | (67.4%) | (54.9%) | 12% |
|
| Liabilities to Assets | 25.4% | 29.3% | 17% |
|
| F-Score | 1 | 3 | 1% |
|
MoonLake Immunotherapeutics did not pass any screens on 10/8/2026.
